Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Phase I NSCLC trials shrink and cluster in major U.S. cities

21

Apr 2026

Phase I NSCLC trials shrink and cluster in major U.S. cities

Between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became increasingly concentrated at the top 20 highest‑volume clinical trial sites largely located in major cities, according to results presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

Trial shows safety of novel KIR-CAR T therapy in solid tumors

20

Apr 2026

Trial shows safety of novel KIR-CAR T therapy in solid tumors

An innovative type of CAR T cell therapy, called KIR-CAR, was shown to be safe, with increasing efficacy corresponding to higher doses of the investigational treatment in nine patients with advanced ovarian cancer, mesothelioma or cholangiocarcinoma (bile duct cancer), according to an early report from an ongoing Phase I dose-escalation clinical trial.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.